vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and RAPID MICRO BIOSYSTEMS, INC. (RPID). Click either name above to swap in a different company.

Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $11.3M, roughly 5.5× RAPID MICRO BIOSYSTEMS, INC.). Cytek Biosciences, Inc. runs the higher net margin — -70.9% vs -110.8%, a 39.8% gap on every dollar of revenue. On growth, RAPID MICRO BIOSYSTEMS, INC. posted the faster year-over-year revenue change (37.3% vs 8.1%). Cytek Biosciences, Inc. produced more free cash flow last quarter ($-1.8M vs $-3.3M). Over the past eight quarters, RAPID MICRO BIOSYSTEMS, INC.'s revenue compounded faster (41.8% CAGR vs 17.7%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

Rapid Micro Biosystems, Inc. develops and manufactures automated microbial detection and quality control solutions for the life sciences industry. Its core products serve biopharmaceutical manufacturers, contract development and manufacturing organizations, operating across key global markets including North America, Europe and Asia-Pacific, helping clients cut testing timelines and improve operational efficiency.

CTKB vs RPID — Head-to-Head

Bigger by revenue
CTKB
CTKB
5.5× larger
CTKB
$62.1M
$11.3M
RPID
Growing faster (revenue YoY)
RPID
RPID
+29.2% gap
RPID
37.3%
8.1%
CTKB
Higher net margin
CTKB
CTKB
39.8% more per $
CTKB
-70.9%
-110.8%
RPID
More free cash flow
CTKB
CTKB
$1.6M more FCF
CTKB
$-1.8M
$-3.3M
RPID
Faster 2-yr revenue CAGR
RPID
RPID
Annualised
RPID
41.8%
17.7%
CTKB

Income Statement — Q4 2025 vs Q4 2025

Metric
CTKB
CTKB
RPID
RPID
Revenue
$62.1M
$11.3M
Net Profit
$-44.1M
$-12.5M
Gross Margin
52.9%
Operating Margin
-9.0%
-108.2%
Net Margin
-70.9%
-110.8%
Revenue YoY
8.1%
37.3%
Net Profit YoY
-557.1%
-29.3%
EPS (diluted)
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
RPID
RPID
Q4 25
$62.1M
$11.3M
Q3 25
$52.3M
$7.8M
Q2 25
$45.6M
$7.3M
Q1 25
$41.5M
$7.2M
Q4 24
$57.5M
$8.2M
Q3 24
$51.5M
$7.6M
Q2 24
$46.6M
$6.6M
Q1 24
$44.9M
$5.6M
Net Profit
CTKB
CTKB
RPID
RPID
Q4 25
$-44.1M
$-12.5M
Q3 25
$-5.5M
$-11.5M
Q2 25
$-5.6M
$-11.9M
Q1 25
$-11.4M
$-11.3M
Q4 24
$9.6M
$-9.7M
Q3 24
$941.0K
$-11.3M
Q2 24
$-10.4M
$-12.6M
Q1 24
$-6.2M
$-13.3M
Gross Margin
CTKB
CTKB
RPID
RPID
Q4 25
52.9%
Q3 25
52.7%
Q2 25
52.3%
Q1 25
48.6%
Q4 24
58.5%
Q3 24
56.3%
Q2 24
54.6%
Q1 24
51.3%
Operating Margin
CTKB
CTKB
RPID
RPID
Q4 25
-9.0%
-108.2%
Q3 25
-17.6%
-145.1%
Q2 25
-23.3%
-167.3%
Q1 25
-36.1%
-161.8%
Q4 24
5.2%
-124.5%
Q3 24
-8.2%
-158.3%
Q2 24
-18.3%
-202.1%
Q1 24
-23.9%
-254.4%
Net Margin
CTKB
CTKB
RPID
RPID
Q4 25
-70.9%
-110.8%
Q3 25
-10.5%
-146.8%
Q2 25
-12.2%
-163.3%
Q1 25
-27.5%
-156.3%
Q4 24
16.8%
-117.6%
Q3 24
1.8%
-148.9%
Q2 24
-22.4%
-190.1%
Q1 24
-13.8%
-237.4%
EPS (diluted)
CTKB
CTKB
RPID
RPID
Q4 25
$-0.26
Q3 25
$-0.26
Q2 25
$-0.27
Q1 25
$-0.26
Q4 24
$-0.22
Q3 24
$-0.26
Q2 24
$-0.29
Q1 24
$-0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
RPID
RPID
Cash + ST InvestmentsLiquidity on hand
$90.9M
$20.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$341.7M
$33.2M
Total Assets
$461.5M
$74.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
RPID
RPID
Q4 25
$90.9M
$20.0M
Q3 25
$93.3M
$18.9M
Q2 25
$75.5M
$18.3M
Q1 25
$95.3M
$18.9M
Q4 24
$98.7M
$16.9M
Q3 24
$162.3M
$22.0M
Q2 24
$177.9M
$37.1M
Q1 24
$168.8M
$22.4M
Stockholders' Equity
CTKB
CTKB
RPID
RPID
Q4 25
$341.7M
$33.2M
Q3 25
$378.6M
$44.3M
Q2 25
$377.6M
$54.5M
Q1 25
$379.6M
$65.5M
Q4 24
$395.7M
$75.4M
Q3 24
$385.5M
$84.4M
Q2 24
$389.1M
$94.6M
Q1 24
$392.6M
$105.9M
Total Assets
CTKB
CTKB
RPID
RPID
Q4 25
$461.5M
$74.9M
Q3 25
$494.9M
$84.4M
Q2 25
$493.3M
$75.6M
Q1 25
$482.6M
$85.4M
Q4 24
$499.5M
$98.2M
Q3 24
$491.2M
$105.8M
Q2 24
$483.7M
$117.1M
Q1 24
$492.1M
$127.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
RPID
RPID
Operating Cash FlowLast quarter
$-771.0K
$-3.2M
Free Cash FlowOCF − Capex
$-1.8M
$-3.3M
FCF MarginFCF / Revenue
-2.9%
-29.6%
Capex IntensityCapex / Revenue
1.6%
0.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.8M
$-31.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
RPID
RPID
Q4 25
$-771.0K
$-3.2M
Q3 25
$-3.9M
$-9.1M
Q2 25
$108.0K
$-9.7M
Q1 25
$-125.0K
$-9.1M
Q4 24
$2.0M
$-9.9M
Q3 24
$13.2M
$-8.6M
Q2 24
$6.2M
$-10.1M
Q1 24
$4.0M
$-15.5M
Free Cash Flow
CTKB
CTKB
RPID
RPID
Q4 25
$-1.8M
$-3.3M
Q3 25
$-4.6M
$-9.1M
Q2 25
$-1.5M
$-10.1M
Q1 25
$-974.0K
$-9.4M
Q4 24
$1.1M
$-10.0M
Q3 24
$12.2M
$-8.8M
Q2 24
$5.2M
$-10.6M
Q1 24
$3.4M
$-16.1M
FCF Margin
CTKB
CTKB
RPID
RPID
Q4 25
-2.9%
-29.6%
Q3 25
-8.7%
-116.4%
Q2 25
-3.2%
-138.6%
Q1 25
-2.3%
-130.2%
Q4 24
1.9%
-121.8%
Q3 24
23.7%
-116.0%
Q2 24
11.0%
-159.8%
Q1 24
7.6%
-287.1%
Capex Intensity
CTKB
CTKB
RPID
RPID
Q4 25
1.6%
0.8%
Q3 25
1.3%
0.9%
Q2 25
3.5%
5.0%
Q1 25
2.0%
4.4%
Q4 24
1.6%
1.2%
Q3 24
2.0%
2.9%
Q2 24
2.3%
6.9%
Q1 24
1.3%
10.4%
Cash Conversion
CTKB
CTKB
RPID
RPID
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.21×
Q3 24
14.05×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

RPID
RPID

Products$9.3M83%
Services$2.0M17%

Related Comparisons